BioTuesdays
Alector
Markets

BTIG starts Alector at buy; PT $28

BTIG initiated coverage of Alector (NASDAQ:ALEC) with a “buy” rating and $28 price target. The stock closed at $15.80 on Nov. 20. Alector is focused on the immune system of the brain as a major player in...

November 21, 2019
Calithera Biosciences
Markets

HCW starts Calithera Biosciences at buy; PT $7

H.C. Wainwright launched coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $7 price target. The stock closed at $3.38 on Nov. 18. Calithera is developing therapies that target cellular metabolic...

November 19, 2019
SELLAS Life Sciences Logo
Markets

Maxim ups SELLAS to buy; sets PT $12

Maxim Group upgraded SELLAS Life Sciences (NASDAQ:SLS) to “buy” from “hold” with a price target of $12 after the company removed a financing overhang. The stock closed at $6.17 on Nov. 14. SELLAS ended the latest...

November 15, 2019
ResTORbio
Markets

SVB Leerink cuts ResTORbio to MP; PT to $2 from $40

SVB Leerink downgraded ResTORbio (NASDAQ:TORC) to “market perform” from “outperform” and slashed its price to $2 from $40 after a failure of first of the company’s two ongoing Phase 3 trials in respiratory infection...

November 15, 2019
Leap Therapeutics
Markets

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

H.C. Wainwright lowered its price target for Leap Therapeutics (NASDAQ:LPTX) to $3.25 from $7.50 after the company decided to re-allocate resources and focus on advancing DKN-01, its anti-Dickkopf-1 antibody, while...

November 15, 2019
Genocea Biosciences
Markets

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

November 15, 2019
Liminal BioSciences
Markets

Liminal BioSciences to begin trading on NASDAQ

Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto...

November 15, 2019
Motus GI Holdings
Markets

AGP cuts PT for Motus GI to $3.75 from $6

Alliance Global Partners lowered its price target for Motus GI Holdings (NASDAQ:MOTS) to $3.75 from $6, reflecting a lower sales multiple and reduced estimates after the company’s third quarter report. The stock closed...

November 15, 2019
Arvinas
Markets

Roth starts Arvinas at buy; PT $35

Roth Capital Partners initiated coverage of Arvinas (NASDAQ:ARVN) with a “buy” rating and $35 price target. The stock closed at $28.38 on Nov. 13. Analyst Zegbeh Jallah writes that Arvinas is one of the leaders in the...

November 14, 2019
GlycoMimetics
Markets

Roth resumes coverage of GlycoMimetics at buy; PT $12

Roth Capital Partners resumed coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and price target of $12. The stock closed at $6.26 on Nov. 13. Analyst Zegbeh Jallah writes that following an August announcement...

November 14, 2019
Bicycle Therapeutics Logo
Markets

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

November 14, 2019
Harpoon Therapeutics
Markets

Roth starts Harpoon Therapeutics at buy; PT $25

Roth Capital Partners launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and price target of $25. The stock closed at $13.51 on Nov. 13. Analyst Zegbeh Jallah writes that Harpoon has a next...

November 14, 2019
Cerus
Markets

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

November 13, 2019
Markets

HCW cuts Sunesis Pharma PT to 50 cents from $1.50

H.C. Wainwright lowered its price target for Sunesis Pharmaceuticals (NASDAQ:SNSS) to 50 cents from $1.50, citing a reduction in the probability of success for the vecabrutinib program to 7% from 8%. The stock closed at...

November 13, 2019
Stoke Therapeutics
Markets

BTIG starts Stoke Therapeutics at buy; PT $46

BTIG launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and $46 price target. The stock closed at $29.79 on Nov. 11. Stoke is focused on technology developed largely by the academic inventors of...

November 12, 2019
Replimune Group Logo
Markets

Roth ups Replimune PT to $30 from $20

Roth Capital Partners raised its price target for Replimune Group (NASDAQ:REPL) to $30 from $20 after the company over the weekend reported evidence of anti-tumor activity for ongoing and expanded programs in cutaneous...

November 11, 2019
ASLAN Pharmaceuticals
Markets

BTIG cuts ASLAN Pharma to neutral; removes PT

BTIG downgraded ASLAN Pharmaceuticals (NASDAQ:ASLN) to “neutral” from “buy” without a price target after the company posted top-line data for Varlitinib, a pan-HER inhibitor, in its Phase 3 TREETOP study in second-line...

November 11, 2019
Innate Pharma Logo
Markets

SVB Leerink starts Innate Pharma at OP; PT $10

SVB Leerink initiated coverage of Innate Pharma (NASDAQ:IPHA) with an “outperform” rating and $10 price target. The stock closed at $6.31 on Nov. 8. Innate is a commercial stage biotech company focused on developing and...

November 11, 2019
Genocea Biosciences
Markets

Stifel ups Genocea Biosciences PT to $18 from $5

Stifel hiked its price target for Genocea Biosciences (NASDAQ:GNCA) to $18 from $5 after raising the probability of success to 20% from 15% for Phase 1 efficacy data of the company’s cancer vaccine, GEN-009. The stock...

November 11, 2019